GENFF (Genflow Biosciences) Buyback Yield %: -10.50 (As of Jul. 02, 2026)


What is Genflow Biosciences Buyback Yield %?

Genflow Biosciences GENFF Buyback Yield % is -10.50 as of Jul. 02, 2026. The stock has 1 warning sign investors should review. Among 745 Biotechnology companies, Genflow Biosciences ranks worse than 53.15% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Genflow Biosciences's current buyback yield was -10.50%.

Genflow Biosciences Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences Buyback Yield % Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
0.00 0.00 0.00 -3.94 -9.86

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -7.30 -10.89 -26.21 -14.34

GENFF vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Genflow Biosciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genflow Biosciences Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genflow Biosciences's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Genflow Biosciences's Buyback Yield % falls into.


Genflow Biosciences Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Genflow Biosciences's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 1.752) / 17.767728
=-9.86%

Genflow Biosciences's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 1.752) / 17.767728
=-9.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -10.50 mean?
Genflow Biosciences (GENFF) has a Buyback Yield % of -10.50 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Genflow Biosciences and its competitors. According to the industry distribution chart, Genflow Biosciences ranks #396 out of 745 companies in the Biotechnology industry, placing it in the top 53.2%.
Is Genflow Biosciences' Buyback Yield % too high?
Genflow Biosciences' current Buyback Yield % is -10.50. Based on the distribution chart, Genflow Biosciences ranks #396 out of 745 companies in the Biotechnology industry, which is below the industry midpoint.
How does Genflow Biosciences' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genflow Biosciences ranks #396 out of 745 companies for Buyback Yield %. This places Genflow Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Genflow Biosciences and its competitors. Genflow Biosciences's current Buyback Yield % is -10.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (GENFF) has a current Buyback Yield % of -10.50. The current Buyback Yield % is -10.50. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Genflow Biosciences (GENFF), the current Buyback Yield % is -10.50 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENF:UKWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.